These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
104 related articles for article (PubMed ID: 17460256)
1. A pharmacokinetic and safety evaluation of an episcleral cyclosporine implant for potential use in high-risk keratoplasty rejection. Lee SS; Kim H; Wang NS; Bungay PM; Gilger BC; Yuan P; Kim J; Csaky KG; Robinson MR Invest Ophthalmol Vis Sci; 2007 May; 48(5):2023-9. PubMed ID: 17460256 [TBL] [Abstract][Full Text] [Related]
2. Preclinical evaluation of a novel episcleral cyclosporine implant for ocular graft-versus-host disease. Kim H; Csaky KG; Gilger BC; Dunn JP; Lee SS; Tremblay M; de Monasterio F; Tansey G; Yuan P; Bungay PM; Lutz RJ; Robinson MR Invest Ophthalmol Vis Sci; 2005 Feb; 46(2):655-62. PubMed ID: 15671296 [TBL] [Abstract][Full Text] [Related]
3. Cyclosporine in collagen particles: corneal penetration and suppression of allograft rejection. Gebhardt BM; Varnell ED; Kaufman HE J Ocul Pharmacol Ther; 1995; 11(4):509-17. PubMed ID: 8574814 [TBL] [Abstract][Full Text] [Related]
4. Pharmacokinetic and toxicity study of an intraocular cyclosporine DDS in the anterior segment of rabbit eyes. Theng JT; Ti SE; Zhou L; Lam KW; Chee SP; Tan D Invest Ophthalmol Vis Sci; 2003 Nov; 44(11):4895-9. PubMed ID: 14578414 [TBL] [Abstract][Full Text] [Related]
5. A novel bioerodible deep scleral lamellar cyclosporine implant for uveitis. Gilger BC; Salmon JH; Wilkie DA; Cruysberg LP; Kim J; Hayat M; Kim H; Kim S; Yuan P; Lee SS; Harrington SM; Murray PR; Edelhauser HF; Csaky KG; Robinson MR Invest Ophthalmol Vis Sci; 2006 Jun; 47(6):2596-605. PubMed ID: 16723476 [TBL] [Abstract][Full Text] [Related]
6. Distribution of cyclosporine A in ocular tissues after topical administration of cyclosporine A cationic emulsions to pigmented rabbits. Daull P; Lallemand F; Philips B; Lambert G; Buggage R; Garrigue JS Cornea; 2013 Mar; 32(3):345-54. PubMed ID: 23023401 [TBL] [Abstract][Full Text] [Related]
7. Efficacy of subconjunctival cyclosporin-containing microspheres on keratoplasty rejection in the rabbit. de Rojas Silva MV; Rodríguez-Ares MT; Sánchez-Salorio M; Lamas Díaz MJ; Cuevas Alvarez J; Vila Jato JL; Capeans Tomé C Graefes Arch Clin Exp Ophthalmol; 1999 Oct; 237(10):840-7. PubMed ID: 10502059 [TBL] [Abstract][Full Text] [Related]
8. A novel cyclosporine a drug-delivery system for prevention of human corneal rejection after high-risk keratoplasty: a clinical study. Shi W; Chen M; Xie L; Liu M; Gao H; Wang T; Wu X; Zhao J Ophthalmology; 2013 Apr; 120(4):695-702. PubMed ID: 23246118 [TBL] [Abstract][Full Text] [Related]
9. Cyclosporine a drug-delivery system for high-risk penetrating keratoplasty: Stabilizing the intraocular immune microenvironment. Zhang T; Li Z; Liu T; Li S; Gao H; Wei C; Shi W PLoS One; 2018; 13(5):e0196571. PubMed ID: 29734357 [TBL] [Abstract][Full Text] [Related]
10. Novel micelle carriers for cyclosporin A topical ocular delivery: in vivo cornea penetration, ocular distribution and efficacy studies. Di Tommaso C; Bourges JL; Valamanesh F; Trubitsyn G; Torriglia A; Jeanny JC; Behar-Cohen F; Gurny R; Möller M Eur J Pharm Biopharm; 2012 Jun; 81(2):257-64. PubMed ID: 22445900 [TBL] [Abstract][Full Text] [Related]
11. [Significance of cyclosporin A absorption for effective immunomodulatory therapy after high-risk keratoplasty]. Bailly N; Dunewa I; Schlattmann P; Rieck PW Ophthalmologe; 2008 May; 105(5):457-62. PubMed ID: 18299847 [TBL] [Abstract][Full Text] [Related]
12. Efficacy and safety of microspheres of cyclosporin A, a new systemic formulation, to prevent corneal graft rejection in rats. Vallelado AI; López MI; Calonge M; Sánchez A; Alonso MJ Curr Eye Res; 2002 Jan; 24(1):39-45. PubMed ID: 12187493 [TBL] [Abstract][Full Text] [Related]
13. [Prolongation of corneal allograft survival in mice with a cyclosporine drug delivery system implant]. Shi W; Xie L; Wang S Zhonghua Yan Ke Za Zhi; 2002 Aug; 38(8):502-5. PubMed ID: 12410993 [TBL] [Abstract][Full Text] [Related]
14. Collagen as a delivery system for hydrophobic drugs: studies with cyclosporine. Gebhardt BM; Kaufman HE J Ocul Pharmacol Ther; 1995; 11(3):319-27. PubMed ID: 8590264 [TBL] [Abstract][Full Text] [Related]
15. High-dose subconjunctival cyclosporine a implants do not affect corneal neovascularization after high-risk keratoplasty. Bock F; Matthaei M; Reinhard T; Böhringer D; Christoph J; Ganslandt T; Cursiefen C Ophthalmology; 2014 Sep; 121(9):1677-82. PubMed ID: 24780407 [TBL] [Abstract][Full Text] [Related]
16. Immunosuppression by a subconjunctival implant releasing dexamethasone in a rabbit model of penetrating keratoplasty. Crouzet E; Garcin T; Gauthier AS; He Z; Perrache C; Delavenne X; Basset T; Peoc'h M; Gain P; Thuret G Br J Ophthalmol; 2018 May; 102(5):692-699. PubMed ID: 29437570 [TBL] [Abstract][Full Text] [Related]
17. In vivo release and retinal toxicity of cyclosporine-loaded intravitreal device. de Almeida FP; Saliba JB; Ribeiro JA; Siqueira RC; Fialho SL; Silva-Cunha A; Jorge R; Messias A Doc Ophthalmol; 2015 Dec; 131(3):207-14. PubMed ID: 26576763 [TBL] [Abstract][Full Text] [Related]
18. [Implantation of FK506 drug delivery system into the anterior chamber for inhibiting corneal rejection in high risk rabbit corneal allograft]. Shi WY; Liu T; Xie LX; Wang SG Zhonghua Yan Ke Za Zhi; 2006 Apr; 42(4):299-304. PubMed ID: 16762204 [TBL] [Abstract][Full Text] [Related]
19. Prevention of high risk corneal graft rejection using cyclosporine A (CsA) incorporated into a collagen matrix. Mahlberg K; Uusitalo RJ; Oksala O Ocul Immunol Inflamm; 1997 Jun; 5(2):101-10. PubMed ID: 9234374 [TBL] [Abstract][Full Text] [Related]
20. In vitro and in vivo release characteristics of Tacrolimus (FK506) from an episcleral drug-delivery implant. Mai S; Lin L; Yang W; Deng X; Xie Z; Zong Y; Li Y; Gao Q J Ocul Pharmacol Ther; 2014 Oct; 30(8):670-80. PubMed ID: 24933028 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]